- Home
- PFD vs CTNM Comparison
PFD vs CTNM Comparison
Compare PFD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- CTNM
- Stock Information
- Founded
- PFD 1990
- CTNM 2009
- Country
- PFD United States
- CTNM United States
- Employees
- PFD N/A
- CTNM N/A
- Industry
- PFD Investment Managers
- CTNM
- Sector
- PFD Finance
- CTNM
- Exchange
- PFD Nasdaq
- CTNM Nasdaq
- Market Cap
- PFD 144.5M
- CTNM 122.9M
- IPO Year
- PFD N/A
- CTNM 2024
- Fundamental
- Price
- PFD $11.14
- CTNM $4.76
- Analyst Decision
- PFD
- CTNM Strong Buy
- Analyst Count
- PFD 0
- CTNM 4
- Target Price
- PFD N/A
- CTNM $22.50
- AVG Volume (30 Days)
- PFD 33.2K
- CTNM 128.0K
- Earning Date
- PFD 01-01-0001
- CTNM 08-12-2025
- Dividend Yield
- PFD 6.30%
- CTNM N/A
- EPS Growth
- PFD N/A
- CTNM N/A
- EPS
- PFD N/A
- CTNM N/A
- Revenue
- PFD N/A
- CTNM N/A
- Revenue This Year
- PFD N/A
- CTNM N/A
- Revenue Next Year
- PFD N/A
- CTNM N/A
- P/E Ratio
- PFD N/A
- CTNM N/A
- Revenue Growth
- PFD N/A
- CTNM N/A
- 52 Week Low
- PFD $8.53
- CTNM $3.35
- 52 Week High
- PFD $11.18
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- PFD 56.49
- CTNM N/A
- Support Level
- PFD $11.09
- CTNM N/A
- Resistance Level
- PFD $11.22
- CTNM N/A
- Average True Range (ATR)
- PFD 0.09
- CTNM 0.00
- MACD
- PFD -0.00
- CTNM 0.00
- Stochastic Oscillator
- PFD 69.36
- CTNM 0.00
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.